 |
 |
 |
 |
 |
 |
 |
||
|
Juvaris BioTherapeutics, Inc. today announced the Company will be presenting at the 9th Annual BIO CEO & Investor Conference on Wednesday, February 14, 2007 at the Waldorf=Astoria Hotel in New York City. Martin D. Cleary, Juvaris' Co-Founder, Chairman and CEO, will provide an overview of the status of Juvaris' business at 2:15p.m. EST in the Conrad Suite. He will explain the significance of the recent Kleiner Perkins Caufield & Byers investment in the Company and the importance of the recent acquisition of intellectual property and other assets from Valentis. He will also update investors on new developments in the Company's collaborations and government grants program. About Juvaris Juvaris BioTherapeutics was created in 2003 to develop an immunotherapeutic product platform for the treatment of infectious diseases and cancers using lipid-DNA complexes. Cationic lipids are formulated with non-coding DNA (plasmid) to create the JuvImmune Immunostimulant, a lipid-DNA complex, which as a single product will have utility in multiple infectious disease and cancer applications. When combined with disease-specific antigens, the technology creates JuvaVax vaccines capable of activating substantial antibody- and cell-mediated immune responses, particularly induction of cytotoxic T lymphocytes (CTL). Immunological responses elicited by the lipid-DNA complexes have been successfully demonstrated in both prophylactic and therapeutic settings in a variety of mammals including rodents, rabbits, cats, dogs and non-human primates. This platform provides the opportunity to develop many disease-specific immunotherapy products, for which there are significant unmet medical needs. Company Contact: |